ARVO 2024: Repeatability of FLIO and erythrocyte velocities in a nonhuman primate glaucoma model

News
Video

Osamah Saeedi, MD, MS, details his ARVO 2024 presentation and the study finding's implications on monitoring and treating glaucoma.

Osamah Saeedi, MD, MS, gives an overview of study results in his ARVO 2024 presentation, "Repeatability of Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) and Erythrocyte Velocities in a Nonhuman Primate Glaucoma Model," which found is that erythrocyte mediated angiography were highly repeatable.

Video Transcript

Editor’s note - The following transcript has been lightly edited for clarity.

Osamah Saeedi MD, MS:

I'm at ARVO 2024. Yesterday, I presented at the ARVO OVI conference, I presented a poster entitled, "The Repeatability and Reproducibility of Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) and Erythrocyte Mediated Angiography in a Non-human Primate Model." The key findings here are we adjusted intraocular pressure in a non-human, in an acute IOP elevation model, in a nonhuman primate. And what we found essentially that the fluorescence lifetime imaging ophthalmoscopy and erythrocyte mediated angiography were highly, erythrocyte mediated angiography were highly repeatable in this model. This is particularly important, because both of these modalities are going to give us further insight, potentially, into the metabolic and non-pressure related changes in glaucoma. So we wanted to make sure that they were not affected by intraocular pressure. While this work is early, it is important as glaucoma specialists that we look for biomarkers for the disease that are not related to intraocular pressure. Hence, knowing the metabolic activity of a tissue, knowing the retinal blood flow, may ultimately help us both monitor the disease early on in, the in the process, as well as develop new treatments that are not related to intraocular pressure. So we have now established that these measurements are highly repeatable in this model of glaucoma, and so we will now look at the long-term changes with elevated intraocular pressure chronically in this model.

Recent Videos
Abby Gillogly Harsch, OD, FAAO, FSLS, shares a specific complex case of scleral lens fitting that she presented on at this year's GSLS.
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
Practice owners testify to the importance of trying new things, not being afraid to fail, and utilizing community as a resource when starting up a new practice.
Optometrists reflect on their residency experiences and provide advice to current residents.
Bonnie An Henderson, MD, the cofounder and program director of EnVision Summit
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
© 2025 MJH Life Sciences

All rights reserved.